Navigation Links
Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
Date:1/18/2013

MIAMI, Jan. 18, 2013 /PRNewswire/ -- Biscayne Pharmaceuticals, Inc. today announced that it has closed a $1.5 million financing.  The new company is developing novel growth hormone-releasing hormone (GHRH) drugs based on recent discoveries by the company's scientific advisor, Dr. Andrew V. Schally , a world-renowned drug researcher and Nobel laureate who pioneered the field of hypothalamic peptide drugs.  Biscayne also announced that it has exclusively licensed intellectual property from the University of Miami that includes worldwide rights to the Schally GHRH technology, including GHRH antagonists with potential in the treatment of cancer and GHRH agonists with potential as an innovative approach to treating heart disease.

Dr. Schally, the Distinguished Leonard M. Miller Professor of Pathology & Professor of Hematology and Oncology at the University of Miami Miller School of Medicine, was awarded the Nobel Prize in Medicine for his breakthrough work on peptide hormones and the brain.  He has had a prolific career as the inventor of many important new drugs, having discovered a number of agents based on luteinizing hormone-releasing hormone (LHRH).  Products stemming from his discoveries continue as mainstays of therapy in oncology and gynecology and generate billions of dollars in sales each year.

Dr. Schally commented, "New GHRH analogs are the latest in a line of synthetic hypothalamic hormones with potential as novel therapeutics for multiple diseases.  A number of our GHRH antagonists have demonstrated promising preclinical activity against many types of cancer, including hard-to-treat prostate cancer, and our GHRH agonists may represent a wholly new regenerative approach to treating heart disease.  GHRH analogs may also have utility in other conditions, such as Alzheimer's disease.  I look forward to working with the accomplished team at Biscayne
'/>"/>

SOURCE Biscayne Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
2. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
3. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
4. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
5. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
6. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
7. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
8. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
9. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
11. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
(Date:10/20/2014)... ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... $1.7 million which brings Q3 orders to $5.8 million and provides ... control projects in North America and one ... continue to bid new projects at record levels," said Peter ... were higher at the end of Q3 than they have been ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2
... April 9, 2012 The University of Southern California Marshall ... announced its 6th Annual Marshall School of Business Leadership ... 11:00 am to 5:30 pm, at Los Angeles, newest landmark, ... (Logo: http://photos.prnewswire.com/prnh/20120409/LA84249LOGO ) A new dynamic ...
... WALTHAM, Mass., April 9, 2012   Syndax Pharmaceuticals, ... that investigators at The University of Texas MD ... have initiated a phase 1/2 study combining Syndax,s ... patients with locally recurrent or distant relapsed metastatic ...
... Carbon Limited today announces that they will be exhibiting at ... sheet of carbon just one atom thick, has been described ... University in 2004, for which the team was awarded a ... commercially. To support this work the UK Government recently ...
Cached Biology Technology:USC Marshall School of Business 6th Annual Leadership Summit 2USC Marshall School of Business 6th Annual Leadership Summit 3Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 2Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 3UK company to demonstrate their commercially effective graphene production process 2
(Date:10/15/2014)... and to an unexpected extent. The outbreak does not ... virus shows a new disease dynamic in regions, where ... the German National Academy of Sciences Leopoldina, acatech – ... Union of the German Academies of Sciences and Humanities ... , In the statement the academies call for the ...
(Date:10/15/2014)... Rosenstiel Award for Distinguished Work in Biomedical Science by ... of genomic instability and its implications for the immune ... to win the Rosenstiel Award; the first, Rod McKinnon, ... the Charles A. Janeway Professor of Pediatrics and Professor ... at the Howard Hughes Medical Institute at Boston Children,s ...
(Date:10/14/2014)... published in Cancer Research shows SIRT6—a protein ... cancers—can promote the development of skin cancers by turning ... of sun-damaged skin cells. , Previously considered protective, SIRT6 ... sirtuins that help regulate genomic stability and prevent some ... repair DNA damage, which can lead to cancer. This ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... OAK RIDGE, Tenn., Jan. 17, 2008 -- Oak ... work for the automotive supplier industry initiated through ... Technologies, or USAutoPARTs collaborative announced today at the ... Made up of a consortium of federal and ...
... Troy, N.Y. - Two theoretical physicists at Rensselaer ... the long-sought-after pathway that an HIV peptide takes ... years of biocomputation and simulation to uncover a ... penetrates the cell membrane. The discovery could help ...
... federal fishery agencies, regional management councils, universities, conservation groups, ... the Cocoanut Grove conference center in Santa Cruz, Calif., ... Groundfish Conference. The Western Groundfish Conference is ... Mary Yoklavich, research biologist with NOAA Fisheries Service. It ...
Cached Biology News:Oak Ridge to lead auto supplier R&D partnership 2Oak Ridge to lead auto supplier R&D partnership 3Researchers reveal HIV peptide's possible pathway into the cell 2Researchers reveal HIV peptide's possible pathway into the cell 3
muscle actin (HUC1-1)...
Anti-Mouse MIP-1g, Biotin (Polyclonal) (rabbit IgG)...
... Anti-NY-ESO-1, clone E978 ... NM_001327 Immunogen : ... Formulation: mouse ascites with ... Assurance: routinely evaluated by ...
... Chicken polyclonal to Opsin 1 ( Abpromise ... Antigen: Synthetic peptide: YEDSTHASIFTYT, corresponding to amino ... and synthetic peptide corresponding to amino acids 18/30 ... and used as immunogen. Entrez ...
Biology Products: